Peer-reviewed veterinary case report
CD25 levels predict survival in dogs with B-cell lymphoma
By R. Sheng et al.·Published in Veterinary and Comparative Oncology·2022·View original on Semantic Scholar →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Prognostic significance of CD25 expression in dogs with a noninvasive diagnosis of B-cell lymphoma treated with CHOP chemotherapy.
- Species:
- dog
Plain-English summary
A study looked at 57 dogs diagnosed with B-cell lymphoma, a type of cancer affecting the lymph nodes, to see if a specific marker called CD25 could predict how long they would live after treatment with CHOP chemotherapy. The dogs had their lymph nodes tested, and those with higher levels of CD25 tended to live longer than those with lower levels, although the differences weren't significant. On average, dogs lived about 272 days after starting treatment. The researchers concluded that while there might be a connection between CD25 levels and survival, more studies are needed to confirm these findings and understand the different types of lymphoma better.
People also search for: dog lymphoma treatment · B-cell lymphoma prognosis in dogs · CHOP chemotherapy for dogs
Abstract
Prior studies have identified high CD25 expression in canine diffuse large B-cell lymphoma as a negative prognostic indicator. The objective of this retrospective study was to evaluate CD25 expression as a prognostic indicator in dogs with B-cell lymphoma (BCL) diagnosed with commonly used noninvasive diagnostics [cytology and flow cytometry (FC)] and treated with CHOP chemotherapy. Lymph node aspirates from 57 dogs with cytologic diagnosis of lymphoma composed of intermediate to large lymphocytes were analyzed with FC. Percentage of neoplastic B-cells expressing CD25 and median fluorescence intensity (MFI) of CD25 were measured. Relationships of CD25 percent positivity and MFI to progression free survival (PFS) and survival time were evaluated. Median survival time (MST) of all dogs was 272 days (95% CI, 196-348 days) and median PFS was 196 days (95% CI, 172-220 days). Higher percentage of B-cells positive for CD25 was associated with decreased risk of death in multivariable analysis (P=.02). Dogs with higher CD25 positivity had longer MST and PFS than dogs with lower CD25 positivity (318 days versus 176 days and 212 days versus 148 days, respectively), but these differences were not significant. CD25 MFI was not significantly associated with outcome. Based on the results of this study, the association of CD25 expression and prognosis in dogs with BCL diagnosed using noninvasive methods should be interpreted with caution. Further evaluation, with studies that include histopathologic differentiation of lymphoma subtypes, is needed.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on Semantic Scholar: https://www.semanticscholar.org/paper/36111442